Platinum‐based doublet chemotherapy, which is used for patients with EGFR‐negative advanced NSCLC, is currently adopted for patients with T790M‐negative EGFR‐mutant advanced NSCLC,3 but the prognosis remains unsatisfactory. Here, EGFR is linked to non-small cell lung carcinoma.